HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phosphoramidon, an endothelin converting enzyme inhibitor attenuates local gastric ischemia-reperfusion injury in rats.

Abstract
Recently increased production of endothelin-1 has been implicated in the pathogenesis of gastric ischemia-reperfusion injury. We have investigated the effects of endothelin converting enzyme inhibition on local gastric ischemia-reperfusion injury in rats by using two metalloprotease inhibitors, phosphoramidon and thiorphan. In presence of exogenous 0.15M HCI intragastrically, local ischemia was induced by the clamping of left gastric artery for 15 min and reperfusion was done for 30 min. In separate group of rats, phosphoramidon (10-60 mg/kg) or thiorphan (60 mg/kg) were given as i.v. bolus injection immediately before the induction of ischemia. Phosphoramidon dose dependently attenuated the macroscopic and microscopic mucosal injuries while thiorphan did not. These results indicate that phosphoramidon-sensitive endothelin converting enzyme activity is highly present in stomach and phosphoramidon, by inhibiting the conversion of big endothelin-1 to endothelin-1 attenuated the gastric mucosal damage in this model.
AuthorsM Hassan, H Kashimura, K Matsumaru, A Nakahara, H Fukutomi, H Muto, K Goto, N Tanaka
JournalLife sciences (Life Sci) Vol. 61 Issue 10 Pg. PL 141-7 ( 1997) ISSN: 0024-3205 [Print] Netherlands
PMID9296343 (Publication Type: Journal Article)
Chemical References
  • Enzyme Inhibitors
  • Glycopeptides
  • Thiorphan
  • Aspartic Acid Endopeptidases
  • Metalloendopeptidases
  • Endothelin-Converting Enzymes
  • phosphoramidon
Topics
  • Animals
  • Aspartic Acid Endopeptidases (antagonists & inhibitors)
  • Endothelin-Converting Enzymes
  • Enzyme Inhibitors (pharmacology)
  • Gastric Mucosa (blood supply)
  • Glycopeptides (pharmacology)
  • Ischemia (prevention & control)
  • Male
  • Metalloendopeptidases
  • Rats
  • Rats, Wistar
  • Reperfusion Injury (prevention & control)
  • Thiorphan (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: